Tranzactioneaza Intra-Cellular Therapies, (US.ITCI) - 69 USD (%) Tranzactioneaza
Indici
Descriere companie
Intra-Cellular Therapies, Inc. (http://www.intracellulartherapies.com/) is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company provides CAPLYTA (lumateperone) for the treatment of schizophrenia in adults. The CAPLYTA is a prescription medicine used to treat the depressive episodes in adults with bipolar I or II, that can be taken alone or with lithium or valproate. The Company's pipeline is focused on three platforms: lumateperone and follow-on compounds, a phosphodiesterase 1 (PDE1) inhibitor platform and discovery platform which includes ITI-333 a novel compound with high affinity at serotonin 5-HT2A, dopamine D1 and mu opioid (MOP) receptors. The Company’s subsidiaries are ITI, Inc. (ITI) and ITI Limited.